APPENDIX 13: ADULT STUDIES IN PAIRWISE ANALYSES - STUDY CHARACTERISTICS TABLES

6.6 PHARMACOLOGICAL INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Monoamine Oxidase Inhibitors (MAOIs)												
Brofaromine (sensitivity analysis)												
FAHLEN1995	SWE	SCID (DSM III R)	38	42%	NR	0%	40	40	Pill Placebo	N/A	7	12
							37	36	Brofaromine	150	7	12
LOTT1997	USA	Clinical Interview (DSM-III R)	37	39%	86%	0%	54	52	Pill Placebo	N/A	7	12
							52	50	Brofaromine	107.2	7	12
VAN-VLIET1992	NED	Clinical Interview (DSM-III R)	33	70%	NR	0%	15	14	Pill Placebo	N/A	7	12
							15	15	Brofaromine	150	7	12

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Monoamine Oxidase Inhibitors (MAOIs)												
Tranylcypromide												
NARDI2010	BRA	SCID (DSM-IV)	36	58%	NR	0%	17	17	Tranylcypromide	60	7	12
							19	19	Tranylcypromide	30	7	12

Study	Country	Interview	Age	%	%	%	N	N	Group	Dose	Freq	Dur

				Female	White	Med	Rand	Post				
Monoamine Oxidase Inhibitors (MAOIs)												
Phenelzine												
GELERNTER1991	USA	ADIS (DSM-III)	37	63%	91%	0	15	15	Pill Placebo	N/A	28	12
							15	12	Alprazolam	1.05	28	12
							15	13	Phenelzine	13.75	28	12
							20	17	CBT (Heimberg), group	2	1	12
Moclobemide												
OOSTERBAAN2001	NED	SCID (DSM III R)	37	0.42	NR	0	27	19	Pill Placebo	N/A	7	15
							27	24	Moclobemide	589	7	15
							28	24	CBT, individual	0.75	1	15

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)												
Duloxetine												
SIMON2010	USA	SCID (DSM-IV)	36	36%	77%	0%	13	13	Duloxetine (60mg)	60	7	18
							15	15	Duloxetine (120mg)	120	7	18

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Selective Serotonin Reuptake Inhibitors (SSRIs)												
Citalopram												
ATMACA2002	TUR	SCID (DSM III R)	30	45%	NR	0%	36	36	Citalopram	36.1	7	8
							35	35	Moclobemide	570.3	7	8

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Selective Serotonin Reuptake Inhibitors (SSRIs)												
Paroxetine												
ALLGULANDER1999	SWE	Clinical Interview (DSM-IV)	39	NR	NR	0	48	48	Pill Placebo	N/A	7	12
							48	44	Paroxetine	NR	7	12
Sertraline												
BLOMHOFF2001	NOR; SWE	Clinical Interview (DSM-IV)	40	60%	NR	NR	95	88	Pill Placebo	N/A	7	24
							98	91	Exposure instructions	0.3	0.7	12
									Pill Placebo	N/A	7	24
							96	87	Sertraline	120.1	7	24
							98	88	Exposure instructions	0.3	0.7	12
									Sertraline	120.1	7	24

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Antipsychotics												
Olanzapine												
BARNETT2002	USA	Clinical Interview (DSM-IV)	NR	NR	NR	0%	5	5	Pill Placebo	N/A	7	8
							7	7	Olanzapine	9	7	8

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Antipsychotics												
Quetiapine												

VAISHNAVI2007	USA	MINI (DSM-IV)	33	53%	67%	0%	5	5	Pill Placebo	N/A	7	8
							10	10	Quetiapine	147	7	8

6.7 PSYCHOLOGICAL INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Cognitive bias modification												
AMIR2009	USA	SCID (DSM-IV)	29	59%	NR	NR	26	22	Computerised Attention Control	0.3	2	4
							22	22	Cognitive Bias Modification	0.3	2	4
AMIR2012	USA	SCID (DSM-IV)	31	71%	47%	27%	26	26	Computerised Attention Control	0.3	2	6
							23	23	Cognitive Bias Modification	0.3333333	2	6
BEARD2011	USA	SCID (DSM-IV)	37	75%	75%	19%	12	12	Computerised Attention Control	0.5	2	4
							20	19	Cognitive Bias Modification	0.5	2	4
BOETTCHER2011	GER; SWZ	SCID (DSM-IV)	38	65%	NR	6%	35	35	Computerised Attention Control	N/A	2	4
							33	33	Cognitive Bias Modification	0	2	4
CARLBRING2012	SWE	SCID (DSM-IV)	37	68%	NR	22%	39	39	Computerised Attention Control	N/A	2	4

							40	40	Cognitive Bias Modification	0	2	4
SCHMIDT2009	USA	SCID (DSM-IV R)	23	44%	67%	NR	20	18	Computerised Attention Control	0.3	2	4
							19	18	Cognitive Bias Modification	0.3	2	4

Study	**Country**	**Interview**	**Age**	**% Female**	**% White**	**% Med**	**N Rand**	**N Post**	**Group**	**Dose**	**Freq**	**Dur**
Individual Cognitive Behavioural Therapy (CBT)												
RENNER2008	USA	SCID (DSM-IV)	19	50%	83%	NR	15	14	Applied Relaxation	0.77	1	NR
							15	14	CBT, individual	2	1	0

Group CBT for paroxetine non-remitters												
HEIMBERG2012	USA	NR	33	40%	45%	NR	29	29	Paroxetine	NR	NR	16
							32	32	CBT (Heimberg), group	0	0	16
									Paroxetine	NR	NR	16

Study	**Country**	**Interview**	**Age**	**% Female**	**% White**	**% Med**	**N Rand**	**N Post**	**Group**	**Dose**	**Freq**	**Dur**
Interpersonal psychotherapy												
BORGE2008	NOR	Clinical Interview (DSM-IV)	38	51%	NR	0%	45	38	Interpersonal Psychotherapy	1.366666667	5	10
							42	35	CBT, group	1.366666667	5	10

										00000 01		

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Short-term psychodynamic psychotherapy												
LEICHSENRING2012	GER	SCID (DSM-IV)	35	0.55	NR	0%	79	79	Wait list	N/A	N/A	0
							207	207	Psychodynamic Psychotherapy	1	1	26
							209	209	CT (Clark & Wells), individual shortened	1	1	26

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Exposure with cognitive enhancers												
Exposure with C-Cycloserine												
GUASTELLA2008	AUS	ADIS (DSM-III R)	35	43%	77%	21%	28	28	Exposure (in vivo)	1.4	1	5
									Pill Placebo	N/A	1	5
							28	28	Exposure (in vivo)	1.4	1	5
									D-Cycloserine	50	1	5
HOFMANN2006	USA	Clinical Interview (DSM-IV)	34	33%	59%	41%	17	15	Exposure (in vivo)	1.4	1	5
									Pill Placebo	N/A	1	5
							15	12	Exposure (in vivo)	1.4	1	5
									D-Cycloserine	50	1	5
HOFMANN2012	USA	SCID	33	43%	72%	0%	82	82	CBT	2.5	1	12

		(DSM-IV)							(Heimberg), group			
									Pill Placebo	N/A	1	5
							87	87	CBT (Heimberg), group	2.5	1	12
									D-Cycloserine	50	1	5

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Exposure with cognitive enhancers												
Exposure with Oxytocin												
GUASTELLA2009	AUS	ADIS (DSM-IV)	42	0%	83%	16%	13	0	Exposure (in vivo)	1.4	1	5
									Pill Placebo	N/A	1	5
							12	0	Exposure (in vivo)	1.4	1	5
									Oxytocin	Unclear	1	5

6.8 PREFERENCE-BASED THERAPY

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Preference-based therapy												
CRASKE2011	USA	Clinical Interview (DSM-IV)	41	0.66	0.61	NR	0	58	Treatment as usual	Unclear	Unclear	26
							0	74	Preference-based (CBT, meds, both)	Unclear	Unclear	26

6.9 SPECIFIC SUBGROUPS

6.9.1 INTERVENTIONS FOR FEAR OF PUBLIC SPEAKING

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Exposure (in vivo) versus waitlist for social anxiety and fear of public speaking												
NEWMAN1994	USA	SCID (DSM III R)	47	50%	NR	0%	18	17	Wait list	N/A	N/A	8
							18	16	Exposure (In vivo)	2	1	8
Exposure (in vivo) versus self-help for social anxiety and fear of public speaking												
TILLFORS2008	SWE	SCID (DSM-IV)	31	81%	NR	NR	19	18	Self-help (internet) with support	0.58	1	9
							19	18	Exposure (In vivo)	0	1	5
									Self-help (internet) no support	0.58	1	9

6.9.2 INTERVENTIONS FOR FEAR OF BLUSHING

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Exposure (In vivo) versus attention training for social anxiety and blushing												
MULKENS2001	NED	SCID (DSM III	NR	23%	NR	0%	14	12	Exposure (In vivo)	1	1	6

		R)					17	14	Attention training / Task Concentration	1	1	6
Attention training versus applied relaxation for social anxiety and fear of blushing, trembling or sweating												
BOGELS2006	NED	SCID (DSM-IV)	32	51%	NR	NR	33	33	CBT, group + Task Concentration	1	1	8
							32	32	CBT, group + Applied Relaxation	1	1	8
Social skills training versus group CBT for social anxiety and fear of blushing, trembling or sweating												
BOGELS2008	NED	SCID (DSM III R)	35	44%	NR	NR	28	28	Social skills training	2	1	12
							27	27	CBT, group	2	1	12

6.9.3 PHYSICAL INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Botulinum toxin (Botox) with paroxetine												
CONNOR2005	USA	Clinical Interview (DSM-IV)	33	53%	55%	0%	20	20	Paroxetine	20	7	8
									Pill placebo	1	1	NR
							20	20	Paroxetine	20	7	8
									Botilium toxin	1	1	NR

6.9.4 INPATIENT INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur

Group CBT versus interpersonal psychotherapy for inpatients												
BORGE2008	NOR	Clinical Interview (DSM-IV)	38	51%	NR	0%	45	38	Interpersonal Psychotherapy	1.4	5	10
							42	35	CBT, group	1.4	5	10

6.9.5 INTERVENTIONS FOR SOCIAL ANXIETY AND COMORBID ALCOHOL MISUSE

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Antidepressant												
Paroxetine												
BOOK2008	USA	SCID (DSM-IV)	29	48%	91%	0%	22	22	Pill placebo	N/A	7	16
							20	20	Paroxetine (40mg)	45	7	16
RANDALL2001a	USA	SCID (DSM-IV)	36	13%	100%	0%	9	9	Pill placebo	N/A	7	8
							6	6	Paroxetine (40mg)	46.7	7	8
Cognitive behavioural therapy												
HAYES2006	USA	SCID (DSM-IV)	20	73%	96%	NR	10	10	CBT, group	1	1	6
							13	13	CBT, group + Alcohol programme	1	1	6

6.9.5 INTERVENTIONS FOR SOCIAL ANXIETY WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Atomoxetine for social anxiety and attention deficit hyperactivity disorder												

ADLER2009	USA	SCID (DSM-IV R)	38	46%	74%	NR	218	166	Pill placebo	N/A	N/A	14
							224	176	Atomoxetine	41.5	14	14

Country: Three letter abbreviations for all countries from which participants were recruited.
Interview: If a structured interview was used, the same of the interview and the diagnostic criteria used.
Age: Mean age of participants.
% **Female**: Percentage of participants enrolled who were female.
% **White**: Percentage of participants enrolled who described themselves white/Caucasian.
% **Med**: Percentage of participants taking medication (e.g. SSRI or benzodiazepine) at baseline. Normally these participants were on a stable dose and agreed not to change their dose during the trial.
N Rand: Number of participants randomised to each group.
N Post: Number of participants who completed assessment at post-treatment.
Group: Name of each group included in the trial.
Dose: For each group, the amount of medication or psychological intervention received. For medication, milligrams per dose (average where possible, otherwise endpoint). For psychological interventions, hours per dose.
Freq: Number of doses per week.
Dur: Number of weeks of intervention. Dose x Freq X Dur = Total amount of medication or psychological intervention received.